Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/4/2025

Management of Delirium

Introduction to Haloperidol Dosage

  • The minimum effective dose of haloperidol for managing delirium is 0.5 mg, which should be administered orally or subcutaneously as needed, according to the Annals of Oncology guideline 1
  • Starting dose: 0.5-1 mg orally (p.o.) or subcutaneously (s.c.) is recommended by the Annals of Oncology guideline 1
  • For older or frail patients: Use lower doses of 0.25-0.5 mg and titrate gradually, as suggested by the Annals of Oncology guideline 1
  • PRN (as needed) dosing: 0.5 or 1 mg p.o. or s.c. every 1 hour as needed, is recommended by the Annals of Oncology guideline 1
  • Administer every 8-12 hours, according to the Annals of Oncology guideline 1

Alternative Medications

  • Olanzapine: 2.5-5 mg p.o. or s.c. (may offer benefit in delirium management), as recommended by the Annals of Oncology guideline 1
  • Quetiapine: 25 mg p.o. (less likely to cause EPSEs), is suggested by the Annals of Oncology guideline 1
  • Aripiprazole: 5 mg p.o. or i.m. (less likely to cause EPSEs), according to the Annals of Oncology guideline 1

Contraindications and Precautions

  • Contraindicated in Parkinson's disease or Lewy body dementia due to risk of EPSEs, as stated by the Annals of Oncology guideline 1
  • May prolong QTc interval - ECG monitoring recommended for intravenous administration, according to the Annals of Oncology guideline 1
  • Patients with hepatic impairment: Dose reduction required, as recommended by the Annals of Oncology guideline 1
  • Elderly patients: Use 0.25-0.5 mg as starting dose, according to the Annals of Oncology guideline 1

Monitoring and Assessment

  • Regular assessment of delirium severity using standardized tools is recommended 1
  • Monitor for extrapyramidal symptoms, as suggested by the Annals of Oncology guideline 1
  • ECG monitoring if using intravenous administration or if patient has cardiac risk factors, according to the Annals of Oncology guideline 1
  • Assess for QTc prolongation, as recommended by the Annals of Oncology guideline 1

General Considerations

  • Pharmacological interventions should be used only after addressing reversible precipitating factors of delirium, as delirium reversibility in palliative care units has been reported to be as high as 50% with appropriate management of underlying causes, according to the Annals of Oncology guideline 1